Publications by authors named "Christopher Keir"

Claim this Profile
P
Patient-reported outcomes associated with cancer screening: a systematic review.
Ashley Kim, Karen C Chung, Christopher Keir, Donald L Patrick

BMC Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer.
Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Christopher Keir

N Engl J Med· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy.
Theodore W Laetsch, Shannon L Maude, Michael C Milone, Kara L Davis, Joerg Krueger, Christopher H Keir

Blood· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia.
Alessandro Crotta, Jie Zhang, Christopher Keir

Curr Med Res Opin· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Building blocks for institutional preparation of CTL019 delivery.
Joseph McGuirk, Edmund K Waller, Muna Qayed, Sunil Abhyankar, Solveig Ericson, Christopher Keir

Cytotherapy· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global Manufacturing of CAR T Cell Therapy.
Bruce L Levine, James Miskin, Keith Wonnacott, Christopher Keir

Mol Ther Methods Clin Dev· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety Follow-Up of Subjects Previously Treated with Non-Replicating Retroviral Vector-Based Gene Therapies.
Ramon Mohanlal, Yuhong Qiu, Ming Zheng, Asmae Mirkou, Kanaka Sridharan, Christopher Keir

Mol Diagn Ther· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.
Jorge E Cortes, Jeffrey H Lipton, Carole B Miller, Lambert Busque, Luke P Akard, Christopher Keir

Clin Lymphoma Myeloma Leuk· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.
Annie Guérin, Medha Sasane, Christopher Hunt Keir, Genevieve Gauthier, Alexander R Macalalad

JAMA Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.
Annie Guerin, Medha Sasane, Genevieve Gauthier, Christopher H Keir, Maryia Zhdavana

J Med Econ· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach.
Anthony Paul Conley, Annie Guerin, Medha Sasane, Genevieve Gauthier, Frances Schwiep, Christopher Hunt Keir

J Gastrointest Cancer· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
Annie Guérin, Lei Chen, Raluca Ionescu-Ittu, Maryna Marynchenko, Roy Nitulescu, Christopher Keir

Curr Med Res Opin· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach.
Anthony Paul Conley, Annie Guérin, Medha Sasane, Geneviève Gauthier, Frances Schwiep, Christopher Hunt Keir

J Gastrointest Cancer· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.
Christopher H Keir, Linda T Vahdat

Expert Opin Biol Ther· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoglycemia-induced anoxic brain injury possibly associated with levofloxacin.
Kenneth R Lawrence, May Adra, Christopher Keir

J Infect· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis